1. Home
  2. FLNC vs MESO Comparison

FLNC vs MESO Comparison

Compare FLNC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluence Energy Inc.

FLNC

Fluence Energy Inc.

HOLD

Current Price

$7.86

Market Cap

1.8B

Sector

Miscellaneous

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.74

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNC
MESO
Founded
2018
2004
Country
United States
Australia
Employees
N/A
108
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
FLNC
MESO
Price
$7.86
$14.74
Analyst Decision
Hold
Strong Buy
Analyst Count
17
1
Target Price
★ $15.71
N/A
AVG Volume (30 Days)
★ 7.2M
160.8K
Earning Date
05-06-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $2,262,830,000.00
N/A
Revenue This Year
$51.23
$629.74
Revenue Next Year
$21.30
$30.65
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.01
$13.05
52 Week High
$33.51
$21.50

Technical Indicators

Market Signals
Indicator
FLNC
MESO
Relative Strength Index (RSI) 33.76 42.64
Support Level $7.01 $14.18
Resistance Level $11.37 $16.06
Average True Range (ATR) 0.41 0.42
MACD 0.05 -0.08
Stochastic Oscillator 25.72 30.73

Price Performance

Historical Comparison
FLNC
MESO

About FLNC Fluence Energy Inc.

Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: